http://jcps.bjmu.edu.cn

中国药学(英文版) ›› 2019, Vol. 28 ›› Issue (4): 238-246.DOI: 10.5246/jcps.2019.04.024

• 【研究论文】 • 上一篇    下一篇

IMB-XH1作为新型新德里金属-β-内酰胺酶-1(NDM-1)抑制剂的研究

韩江雪1, 肖春玲1, 甘茂罗1, 李兴华1, 王颖1, 郑佳音2, 李东升1, 刘琛楠1, 关艳1, 蒙建州1, 黄树超1, 刘忆霜1*   

  1. 1. 中国医学科学院 北京协和医学院 医药生物技术研究所, 国家新药(微生物)筛选实验室, 北京 100050
    2. 首都医科大学 神经生物学系, 北京 100069
  • 收稿日期:2019-02-11 修回日期:2019-03-11 出版日期:2019-04-30 发布日期:2019-03-14
  • 通讯作者: Tel.: +86-010-63020226, E-mail: rememberfrost@163.com
  • 基金资助:

    Natural Sciences Foundation of China (NSFC, Grant No. 81872913), the CAMS Initiative for Innovative Medicine (Grant No.2016-I2M-1-013), the Fundamental Research Funds for Central Public-interest Scientific Institution (Centre for Tuberculosis) (Grant No. 2016ZX310183-3) and the National High-tech R&D Program (863 Program, Grant No. 2015AA020911).

IMB-XH1 identified as a novel inhibitor of New Delhi metallo-β-lactamase-1

Jiangxue Han1, Chunling Xiao1, Maoluo Gan1, Xinghua Li1, Ying Wang1, Jiayin Zheng2, Dongsheng Li1, Chennan Liu1, Yan Guan1, Jianzhou Meng1, Shuchao Huang1, Yishuang Liu1*   

  1. 1. National Key Laboratory for Screening New Microbial Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
    2. Department of Neurobiology, Capital Medical University, Beijing 100069, China
  • Received:2019-02-11 Revised:2019-03-11 Online:2019-04-30 Published:2019-03-14
  • Contact: Tel.: +86-010-63020226, E-mail: rememberfrost@163.com
  • Supported by:

    Natural Sciences Foundation of China (NSFC, Grant No. 81872913), the CAMS Initiative for Innovative Medicine (Grant No.2016-I2M-1-013), the Fundamental Research Funds for Central Public-interest Scientific Institution (Centre for Tuberculosis) (Grant No. 2016ZX310183-3) and the National High-tech R&D Program (863 Program, Grant No. 2015AA020911).

摘要:

革兰氏阴性菌的耐药问题日益严峻, 已经引起了公众的广泛关注。产新德里金属β-内酰胺酶(NDM-1)超级细菌对几乎所有的β-内酰胺类抗生素耐药。然而临床现有的β-内酰胺酶抑制剂对NDM-1等金属β-内酰胺酶无效, 因此, 临床上迫切需要有效NDM-1抑制剂。在这项研究中, 优化了NDM-1抑制剂的高通量筛选模型。应用该模型筛选NDM-1抑制剂, 并从不同来源的化合物样品中筛选得到一种NDM-1的抑制剂IMB-XH1。研究发现IMB-XH1β-内酰胺类抗生素联合使用可以提高表达NDM-1的大肠埃希菌E.coli BL21(DE3)(pET-30a(+)-NDM-1)β-内酰胺类抗生素的敏感性。酶促动力学研究表明IMB-XH1NDM-1的非竞争性抑制剂。IMB-XH1还具有对其他金属β-内酰胺酶的抑制活性, IMP-4, ImiSL1IMB-XH1作为一种新型的NDM-1抑制剂, 值得进一步对其活性评价和作用机制进行深入研究。 

关键词: NDM-1, 金属-β-内酰胺酶抑制剂, 高通量筛选, 细菌耐药

Abstract:

The problem of drug resistance of Gram-negative bacteria has become increasingly serious and has aroused widespread public concern. The super bacteria producing New Delhi metallo-beta-lactamase (NDM-1) are resistant to almost all β-lactam antibiotics. However, clinically existing β-lactamase inhibitors are ineffective against metallo-β-lactamases (MBLs) including NDM-1. Therefore, effective NDM-1 inhibitors are urgently needed. In this study, a high-throughput screening model for NDM-1inhibitors was optimized and used to screen NDM-1 inhibitors. As a result, IMB-XH1 was screened out as a novel NDM-1 inhibitor from 52 100 compounds of different sources. The combined use of IMB-XH1 can increase the sensitivity of E. coli BL21(DE3) (pET-30a(+)-NDM-1) to β-lactam antibiotics. Enzymatic kinetic studies indicate that IMB-XH1 is a non-competitive inhibitor of NDM-1 and also has inhibitory activity against other MBLs such as IMP-4, ImiS and L1. As a novel NDM-1 inhibitor, its activity and mechanism of action need to be further explored.  

Key words: NDM-1, Metallo-β-lactamases inhibitor, High throughput screening, Bacterial resistance

中图分类号: 

Supporting: